Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct 31;4(10):e006488.
doi: 10.1136/bmjopen-2014-006488.

Computerised cognitive behaviour therapy for depression in adolescents: study protocol for a feasibility randomised controlled trial

Barry Wright  1 , Lucy Tindall  1 , Elizabeth Littlewood  2 , Joy Adamson  2 , Victoria Allgar  2 , Sophie Bennett  1 , Simon Gilbody  2 , Chrissie Verduyn  3 , Ben Alderson-Day  1 , Lisa Dyson  2 , Dominic Trépel  2 , Shehzad Ali  2
Affiliations
Randomized Controlled Trial

Computerised cognitive behaviour therapy for depression in adolescents: study protocol for a feasibility randomised controlled trial

Barry Wright et al. BMJ Open. .

Abstract

Introduction: The 1 year prevalence of depression in adolescents is about 2%. Treatment with antidepressant medication is not recommended for initial treatment in young people due to concerns over high side effects, poor efficacy and addictive potential. Evidence suggests that cognitive behaviour therapy (CBT) is an effective treatment for depression and is currently one of the main treatment options recommended in adolescents. Given the affinity young people have with information technology they may be treated effectively, more widely and earlier in their illness evolution using computer-administered CBT (CCBT). Currently little is known about the clinical and resource implications of implementing CCBT within the National Health Service for adolescents with low mood/depression. We aim to establish the feasibility of running a fully powered randomised controlled trial (RCT).

Methods and analysis: Adolescents aged 12-18 with low mood/depression, (scoring ≥20 on the Mood and Feelings Questionnaire (MFQ)), will be approached to participate. Consenting participants will be randomised to either a CCBT programme (Stressbusters) or accessing selected websites providing information about low mood/depression. The primary outcome measure will be the Beck Depression Inventory (BDI). Participants will also complete generic health measures (EQ5D-Y, HUI2) and resource use questionnaires to examine the feasibility of cost-effectiveness analysis. Questionnaires will be completed at baseline, 4 and 12-month follow-ups. Progress and risk will be monitored via the MFQ administered at each treatment session. The acceptability of a CCBT programme to adolescents; and the willingness of clinicians to recruit participants and of participants to be randomised, recruitment rates, attrition rates and questionnaire completion rates will be collected for feasibility analysis. We will estimate 'numbers needed' to plan a fully powered RCT of clinical and cost-effectiveness.

Ethics and dissemination: The current trial protocol received a favourable ethical opinion from Leeds (West) Research and Ethics Committee. (Reference: 10/H1307/137).

Trial registration number: ISRCTN31219579.

Keywords: MENTAL HEALTH.

PubMed Disclaimer

References

    1. Papanikolaou K, Richardson C, Pehlivanidis A, et al. . Efficacy of anti-depressants in child and adolescent depression: a meta-analytic study. J Neural Transm 2005;113:399–415 - PubMed
    1. National Institute for Health and Clinical Excellence. Depression in children and young people: identification and management in primary, community and secondary care. Clin Guidel 2005;2. http://guidance.nice.org.uk/CG28 (accessed 7 Oct 2011).
    1. European Medicines Agency. European Medicines Agency finalises review of anti-depressants in children and adolescents. European Medicines Agency, 2005. http://www.emea.europa.eu/pdfs/human/press/pr/12891805en.pdf (accessed 7 Oct 2011).
    1. European Medicines Agency. European Medicines Agency adopts a positive opinion for the use of Prozac in the treatment of children and adolescents suffering from depression. European Medicines Agency, 2006. http://www.emea.europa.eu/pdfs/human/press/pr/20255406en.pdf (accessed 7 Oct 2011).
    1. Priest RG, Vize C, Roberts A, et al. . Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. BMJ 1996;313:858–9 - PMC - PubMed

Publication types

Associated data

LinkOut - more resources